AVR Stock Overview A structural heart company, discovers, develops, and commercializes medical devices to enhance the quality of life for patients with aortic stenosis. More details
Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Anteris Technologies Global Corp. Competitors Price History & Performance
Summary of share price highs, lows and changes for Anteris Technologies Global Historical stock prices Current Share Price AU$8.85 52 Week High AU$23.93 52 Week Low AU$8.50 Beta 0.73 1 Month Change -6.74% 3 Month Change -29.14% 1 Year Change -53.91% 3 Year Change -31.13% 5 Year Change -26.25% Change since IPO -88.36%
Recent News & Updates
Anteris Technologies Global Corp. has completed an IPO in the amount of $88.8 million. Dec 14
New major risk - Shareholder dilution Dec 13
Anteris Technologies Global Corp. has completed an IPO in the amount of $88.8 million. Dec 13
Consensus revenue estimates increase by 12%, EPS downgraded Sep 28 Anteris Technologies SPONSORED ADR to Be Deleted from OTC Equity Sep 13
First half 2024 earnings released: AU$2.75 loss per share (vs AU$2.01 loss in 1H 2023) Aug 26 See more updates
Anteris Technologies Global Corp. has completed an IPO in the amount of $88.8 million. Dec 14
New major risk - Shareholder dilution Dec 13
Anteris Technologies Global Corp. has completed an IPO in the amount of $88.8 million. Dec 13
Consensus revenue estimates increase by 12%, EPS downgraded Sep 28 Anteris Technologies SPONSORED ADR to Be Deleted from OTC Equity Sep 13
First half 2024 earnings released: AU$2.75 loss per share (vs AU$2.01 loss in 1H 2023) Aug 26 Anteris Technologies Ltd has filed a Follow-on Equity Offering in the amount of AUD 30 million. Jul 25
Anteris Technologies and v2vmedtech Announce Concept Lock of Next Generation Mitral and Tricuspid Repair System as VClip Passes Animal Study Jul 01
Shareholders May Not Be So Generous With Anteris Technologies Ltd's (ASX:AVR) CEO Compensation And Here's Why May 22 Anteris Technologies Ltd, Annual General Meeting, May 29, 2024
Full year 2023 earnings: EPS and revenues miss analyst expectations Feb 29 Anteris Technologies Ltd has completed a Follow-on Equity Offering in the amount of AUD 40 million. Oct 26
First half 2023 earnings released: AU$2.01 loss per share (vs AU$1.73 loss in 1H 2022) Aug 26
Anteris Technologies Ltd Announces DurAVR THV Demonstrates Exceptional Results in Second Valve-in-Valve Case Aug 15
Anteris Technologies Announces First Successful Implantation of Duravr™ Thv in A Valve-In-Valve Procedure Aug 01
Full year 2022 earnings released: AU$3.32 loss per share (vs AU$3.09 loss in FY 2021) Feb 28 Anteris Technologies Ltd has completed a Follow-on Equity Offering in the amount of AUD 35.000016 million. Feb 10
Anteris Technologies Ltd announced that it expects to receive AUD 50 million in funding from Yorkville Advisors Global LP Feb 07
Anteris Technologies Ltd Announces 12 Month Results for Anteris DurAVRTM Transcatheter Heart Valve Aortic Stenosis First in Human Study Jan 16 Anteris Technologies Ltd Announces Formal Results of A Comparative Study to Investigate Aortic Flow Physiology by Cardiac MRI (cMRI) in Five Patients Who Received A DurAVR Transcatheter Aortic Valve (First- In-Human) Anteris Technologies Ltd Announces Results Demonstrating Restoration of Normal Pre-Disease Flow
Anteris Technologies Announces Presentation of First-In-Human Data for its Novel TAVR Product, DurAVR™ at the 2022 Annual TCT Congress in Boston Sep 14
First half 2022 earnings released: EPS: AU$0 (vs AU$1.58 loss in 1H 2021) Aug 25
Dr. Martin Leon, MD Joins Global Medical Advisory Board of Anteris Technologies Ltd Jul 13
Dr. Martin Leon, MD Joins Global Medical Advisory Board of Anteris Technologies Ltd Jul 12
Anteris Technologies Ltd Provides Update on First In Human DurAVR THV Study Jul 11 Anteris Announces 6 Month Follow Up of First Cohort of 5 Patients Jun 21
Anteris Technologies Ltd Announces Successful Completion of Second First-In-Human Study May 31
Anteris Technologies Ltd Announces Expansion of First in Human Trial May 26
Anteris Technologies Ltd Appoints Dion Stub to Medical Advisory Board May 25 Anteris Technologies Ltd has completed a Follow-on Equity Offering in the amount of AUD 27.6 million. Mar 05
Anteris Technologies Ltd announced that it has received AUD 27.6 million in funding from Perceptive Advisors LLC Anteris Technologies Ltd announced that it expects to receive AUD 27.6 million in funding from Perceptive Advisors LLC Mar 03
Anteris Technologies Ltd, Annual General Meeting, May 19, 2022 Feb 25 Medicus Sciences Acquisition Corp. (NasdaqCM:MSAC) (MSAC) cancelled the acquisition of Anteris Technologies Ltd (ASX:AVR). Feb 17
Medicus Sciences Acquisition Corp. (NasdaqCM:MSAC) (MSAC) signed a non-binding letter of intent to acquire Anteris Technologies Ltd (ASX:AVR). Feb 10
Medicus Sciences Acquisition Corp. (NasdaqCM:MSAC) (MSAC) signed a non-binding letter of intent to acquire Anteris Technologies Ltd (ASX:AVR). Feb 09
Anteris Technologies Ltd Reports Successful Interim Results for the First-In-Human Trial Jan 24
Anteris Technologies Ltd Reports New Patent Application for ADAPT Jan 06
Independent Chairman of the Board exercised options to buy AU$58k worth of stock. Dec 11
First half 2021 earnings released: AU$1.58 loss per share (vs AU$1.01 loss in 1H 2020) Aug 30
Anteris Technologies Ltd announced that it has received AUD 9 million in funding Aug 10
Increases to CEO Compensation Might Be Put On Hold For Now at Anteris Technologies Ltd (ASX:AVR) Jul 08
Anteris Technologies Ltd Announces Successful Completion of Proof of Concept (Poc) Animal Study Jun 15
Anteris Technologies Ltd has completed a Follow-on Equity Offering in the amount of AUD 2.327895 million. Jun 01
Anteris Technologies Ltd announced that it expects to receive AUD 2.327895 million in funding May 24
Increases to Anteris Technologies Ltd's (ASX:AVR) CEO Compensation Might Cool off for now May 07
Anteris Technologies Ltd, Annual General Meeting, May 14, 2021 Mar 15
New 90-day high: AU$5.52 Feb 23
Does Anteris Technologies' (ASX:AVR) CEO Salary Compare Well With The Performance Of The Company? Feb 21
Full year 2020 earnings released Feb 20
Anteris Technologies Ltd, Annual General Meeting, May 14, 2021 Feb 18
Anteris Technologies Ltd has completed a Follow-on Equity Offering in the amount of AUD 1.171499 million. Jan 22
New 90-day high: AU$4.30 Jan 08
Anteris Technologies Ltd has completed a Follow-on Equity Offering in the amount of AUD 1.068135 million. Dec 30
Anteris Technologies Announces Resignation of Yanheng Wu as A Non-Executive Director on the Board Dec 17
Anteris Technologies Ltd (ASX:AVR) Insiders Have Been Selling Dec 10
New 90-day low: AU$3.50 Nov 12
Anteris Technologies Ltd Reports Interim Results from Anti-Calcification Study Nov 10
Anteris Technologies Limited Announces DurAVR Valve Patient Outcomes Oct 11
First half earnings released Aug 21
New 90-day low - AU$4.30 Jul 17 Shareholder Returns AVR AU Medical Equipment AU Market 7D -2.1% 0.8% -1.0% 1Y -53.9% 1.9% 7.5%
See full shareholder returns
Return vs Market: AVR underperformed the Australian Market which returned 7.5% over the past year.
Price Volatility Is AVR's price volatile compared to industry and market? AVR volatility AVR Average Weekly Movement 8.4% Medical Equipment Industry Average Movement 8.3% Market Average Movement 8.0% 10% most volatile stocks in AU Market 16.7% 10% least volatile stocks in AU Market 3.1%
Stable Share Price: AVR has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: AVR's weekly volatility (8%) has been stable over the past year.
About the Company Anteris Technologies Global Corp., a structural heart company, discovers, develops, and commercializes medical devices to enhance the quality of life for patients with aortic stenosis. Its lead product candidate is the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also devlops ADAPT anti-calcification tissue, an anti-calcification preparation that transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta.
Show more Anteris Technologies Global Corp. Fundamentals Summary How do Anteris Technologies Global's earnings and revenue compare to its market cap? AVR fundamental statistics Market cap AU$318.07m Earnings (TTM ) -AU$115.11m Revenue (TTM ) AU$4.53m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) AVR income statement (TTM ) Revenue US$2.83m Cost of Revenue US$833.67k Gross Profit US$1.99m Other Expenses US$73.76m Earnings -US$71.77m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -2.00 Gross Margin 70.51% Net Profit Margin -2,538.93% Debt/Equity Ratio 37.7%
How did AVR perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/26 15:11 End of Day Share Price 2024/12/24 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Anteris Technologies Global Corp. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Andrew Scott CGS International Peter Niu CLSA Jason Kolbert Maxim Group
Show 0 more analysts 
